



# 10<sup>th</sup> International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain

## WORD OF WELCOME

Dear Colleagues and Friends,

It is with great enthusiasm that we invite you to join us for the 10th International Transplant and Cellular Therapy Course, taking place from 5–7 September 2025 in the vibrant city of Barcelona, Spain.

This milestone event represents a decade of excellence in the field of transplantation and cellular therapy. Over the years, this course has become a beacon of cutting-edge education, science, and meaningful connections among professionals dedicated to advancing patient care.

Barcelona, renowned for its rich history, stunning architecture, and dynamic culture, provides the perfect backdrop for this gathering of global thought leaders, experts, and rising stars in the field. Together, we will share clinical experiences, translational and basic research, and discuss future directions that promise to shape the landscape of transplant and cellular therapy for years to come.

Whether you are a senior specialist or a young professional eager to learn, this course offers a unique platform to engage in high-quality educational sessions, interactive discussions, and networking opportunities. There will be simultaneous and combined tracks focused on adults, paediatrics, and nurses, ensuring tailored content for diverse professional backgrounds.

Mark your calendars and let us celebrate this landmark 10th edition together, continuing to build on the foundation of progress and excellence we have created as a community.

With warm regards,

Fabio Ciceri / *Scientific Council Chair with Research & Sciences Portfolio*

Esra Gülderen / *EBMT Trainee Committee Co-Chair*

Mette Hazenberg / *EBMT Treasurer*

Claire Horgan / *EBMT Educational Task Force Representative for PDWP*

Krzysztof Kalwak / *PDWP Chair*

Michelle Kenyon / *President, Nurses Group*

Donal McLornan / *Scientific Council Co-Chair with Research & Sciences Portfolio*

Hilda Mekelenkamp / *President-Elect, Nurses Group*

Mohamad Mohty / *EBMT Past President, 2014–2018*

Alex Rampotas / *EBMT Trainee Committee Co-Chair*

Annalisa Ruggeri / *Scientific Council Representative with Education Portfolio*

Anna Sureda / *EBMT President*



# 10<sup>th</sup> International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain

Friday, 5 September 2025  
Main Track | *Paranimf*

09:00 – 09:35

## Welcome & Introduction

**Chairs:** Anna Sureda (ES) & Alex Rampotas (UK)

09:00 – 09:15

The EBMT: 2025 and beyond

Anna Sureda (ES)

09:15 – 09:25

The Next-Gen: The EBMT Trainee Committee

Alex Rampotas (UK)

09:25 – 09:35

The EBMT Exam: Future Plans

Isabel Sanchez-Ortega (ES)

09:35 – 10:45

## Session I: Transplantation and Cellular Therapy: Fundamentals and Framework

**Chairs:** Candice Hendricks (RSA) & John Snowden (UK)

09:35 – 09:50

Hematopoietic cell transplantation: Why and How It Works?

John Snowden (UK)

09:50 – 10:05

HLA System and donor selection

Neema Mayor (UK)

10:05 – 10:20

CAR-T: The Game Changers

Alberto Mussetti (ES)

10:20 – 10:30

*Case presentation:*

Post-transplant Cyclophosphamide as GvHD prophylaxis in Matched Sibling

Donor in patients with  $\beta$ -Thalassemia Major – A Single Centre Experience

Reham Khalaf (EG)

10:30 – 10:40

*Case presentation:*

Post-CART viral reactivations in paediatric patients:

experience in a tertiary care centre

Alicia Pablos Lopez (ES)

10:40 – 10:45

Discussion and Q&A

10:45 – 11:15

## Coffee Break

11:15 – 12:30

## Session II: Transplant Science

**Chairs:** Annalisa Ruggeri (IT) & Luca Vinci (DE)

11:15 – 11:30

HSC Mobilization, Collection, Processing and Preservation

Sara Vallejo Diez (ES)

11:30 – 11:45

Conditioning regimen and intensity

Florent Malard (FR)

11:45 – 12:00

Engraftment and Graft Dynamics

Annalisa Ruggeri (IT)

12:00 – 12:10

*Case presentation:*

Severe and fatal central nervous system toxicity after fludarabine, thiotepa and

melfalan conditioning for allogeneic stem cell transplantation

Pleun Schonewille (NL)

12:10 – 12:30

Discussion and Q&A

12:30 – 13:15

## Lunch Break

13:15 – 14:00

## Industry Symposium by Therakos:

**“Uncovering emerging evidence to treat GvHD with ECP - Mastering the art of GvHD therapy”**

13:15 – 13:20

Introduction

**Prof Anna Sureda**, Catalan Institute of Oncology, Duran I Reynals Hospital, Spain

13:20 – 13:35

How to treat GvHD with ECP – current real-world management of GvHD in Spain

**Dr Guillermo Ortí**, University Hospital Vall d'Hebron, Spain

13:35 – 13:50

Evidence for treatment of chronic GvHD using ECP – a future backbone for GvHD therapy

**Dr Laura Fox**, University Hospital Vall d'Hebron, Spain

13:50 – 14:00

Discussion





# 10<sup>th</sup> International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain

Friday, 5 September 2025  
Main Track | *Paranimf*

14:00 – 15:30

## Session III: GVHD

**Chairs:** Mette Hazenberg (NL) & Fabio Ciceri (IT)

14:00 – 14:15

GVHD Biology: What We Know So Far

Mette Hazenberg (NL)

14:15 – 14:30

Acute GVHD: Diagnosis, Prevention, and Treatment

Zinaida Peric (HR)

14:30 – 14:45

The Forgotten Site: Stomach GVHD in Allogeneic Stem Cell Transplantation

Jana Gawron (DE)

14:45 – 14:55

*Case presentation:*

Effective treatment with Mesenchymal Stromal Cells for refractory Graft-Versus-Host

Disease after allo-HCT complicated by BK virus-associated haemorrhagic cystitis in a patient with AML

Maddalena V. Ponti (IT)

14:55 – 15:05

*Case presentation:*

Hyperbilirubinemia in the 5th Month Post-Allogeneic Transplantation

Marina Herrero (ES)

15:05 – 15:30

Discussion and Q&A

15:30 – 16:00

## Coffee Break

16:00 – 17:15

## Session IV: Late Complications, Ethics and Patient Perspectives

**Chairs:** Carmelo Gurnari (IT) & Giorgio Orofino (IT)

16:00 – 16:15

Late Complications after transplantation

Michelle Kenyon (UK)

16:15 – 16:30

Effective Communication for Transplant and CT Physicians

Carmelo Gurnari (IT)

16:30 – 16:40

CAR-T survivorship

Anna Barata (US)

16:40 – 16:50

Patient and caregiver outcomes after CAR-T therapy

David Aguilar Prieto (ES)

16:50 – 17:00

*Case presentation:*

Late cytopenia post-CAR T-cell infusion and clonal haematopoiesis: a case report Desirée Eboli (IT)

17:00 – 17:15

Discussion and Q&A

17:15 – 18:00

## Keynote Lecture

**Chair:** Alex Rampotas (UK)

Endothelia and early complications after HCT

Enric Carreras (ES)

18:00 – 18:45

## Poster Session

Further details about the poster presenters can be found on the next page.



# 10<sup>th</sup> International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain

Friday, 5 September 2025  
Poster Session | Foyer

18:00 – 18:45

## Poster Session

**Moderators:** Annalisa Ruggeri (IT) & Krzysztof Kałwak (PL)

<b>Poster 1</b>	Cutaneous chronic graft-versus-host disease mimicking acanthosis nigricans	Lucas Anastacio (BR)
<b>Poster 2</b>	Early CMV, Adenovirus, BKV and HHV-6 coinfection following allogeneic Hematopoietic stem cell transplantation: diagnostic and therapeutic barriers in a developing country	Lucas Anastacio (BR)
<b>Poster 3</b>	An unexpected guest: cerebral toxoplasmosis in a paediatric patient after Hematopoietic stem cell transplantation	Miriam Cañada (ES)
<b>Poster 4</b>	Experience with maribavir in resistant/ refractory cytomegalovirus (cmv) infection in paediatric stem cell transplant recipients	Laia Garcia (ES)
<b>Poster 5</b>	Extensive ileitis in early phase after allogeneic hematopoietic stem cell transplantation	Irene Gorostidi (ES)
<b>Poster 6</b>	Long-Term Dual Remission of Therapy-Related AML and Multiple Myeloma Using Stored Autologous Stem Cells and Haploidentical Transplant	Yashashree Gupta (UK)
<b>Poster 7</b>	Three Transplants and Beyond: A Complex Case of Hypoplastic MDS with Rare HLA Haplotype, Graft Failures, and EBV-Driven CNS Lymphomatoid Granulomatosis	Shreyas Hanmantgad (UK)
<b>Poster 8</b>	A complex case of chronic GVHD presenting with serositis	Josephine Lucero (CA)
<b>Poster 9</b>	Immunologic predictive factors for CMV reactivation in SR-cGVHD patients treated with ruxolitinib	Leonardo Maia (PT)
<b>Poster 10</b>	Machine Learning-Based Prediction of Functional Recovery in Spinal Cord Injury Patients Undergoing Autologous Mesenchymal Stem Cell Transplantation: A Retrospective Study from East Java	Bidayatul Masulah (NL)
<b>Poster 11</b>	The Reveal of the Aetiology of Secondary Myelofibrosis by a Unique Post Transplant Complication	Dina Osman (UK)
<b>Poster 12</b>	Toxic Epidermal Necrolysis Mimicking Severe Cutaneous aGVHD Post Allogeneic HSCT: A Diagnostic Challenge	Titas Tiskevicius (LT)



# 10<sup>th</sup> International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain

Saturday, 6 September 2025  
Main Track | *Paranimf*

09:00 – 11:00	<b>Session V: Indications for allogeneic HCT in Adults</b> <b>Chairs:</b> Donal McLornan (UK) & Moniek de Witte (NL)	
09:00 – 09:30	Introductory Case-based: Indications of HCT in AML Indications of HCT in AML	Alessandro Criscimanna (IT) Fabio Ciceri (IT)
09:30 – 10:00	Introductory Case-based: Indications of HCT in MDS Indications of HCT in MDS	Piotr Kacprzyk (PL) Joanna Drozd-Sokołowska (PL)
10:00 – 10:30	Introductory Case-based: Indications of HCT in MPN Indications of HCT in MPN	Yousif Hameed (UK) Donal McLornan (UK)
10:30 – 11:00	Introductory Case-based: Indications of HCT in Bone marrow failures Indications of HCT in Bone marrow failures	Jamie Macleod (UK) José Cilleruelo (UK)
11:00 – 11:30	<b>Coffee Break</b>	
11:30 – 13:00	<b>Session VI: Transforming Care: HCT and CAR-T Therapies</b> <b>Chairs:</b> Raffaella Greco (IT) & Sebastian Giebel (PL)	
11:30 – 11:45	Indications of HCT in ALL	Sebastian Giebel (PL)
11:45 – 12:00	CAR-T for ALL	Mike Northend (UK)
12:00 – 12:15	CAR-T for Myelofibrosis	Alex Rampotas (UK)
12:15 – 12:30	The alternative HCT: Autoimmune diseases	Tobias Alexander (DE)
12:30 – 12:45	Emerging CAR-T Indications in Autoimmune diseases	Raffaella Greco (IT)
12:45 – 13:00	Discussion and Q&A	
13:00 – 14:00	<b>Lunch Break</b>	
14:00 – 15:15	<b>Session VII: Lymphoma: Bridging Transplant and CAR-T Therapies</b> <b>Chairs:</b> Anna Sureda (ES) & Alex Rampotas (UK)	
14:00 – 14:15	Indications of HCT in Lymphoma	Ali Bazarbachi (LB)
14:15 – 14:30	CAR-T for Lymphoma	Anna Sureda (ES)
14:30 – 14:45	CAR-T Complications	Valentín Ortiz-Maldonado (ES)
14:45 – 14:55	<i>Case Presentation:</i> Cyclosporine-Associated Central Pontine Myelinolysis Presenting as Peduncular Hallucinoses Following Allogeneic Hematopoietic Stem Cell Transplantation	Camila Donadel (BR)
14:55 – 15:05	<i>Case Presentation:</i> Hepatic Graft-versus-Host Disease Following Brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma after Allogeneic Transplantation	Elena Bechtold (ES)
15:05 – 15:15	Discussion and Q&A	
15:15 – 15:45	<b>Coffee Break</b>	



# 10<sup>th</sup> International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain

Saturday, 6 September 2025  
Main Track | *Paranimf*

15:45 – 17:00

## Session VIII: Advances and Challenges in Multiple Myeloma

**Chairs:** Adrian Mosquera Orgueira (ES) & Luis Gerardo Rodríguez-Lobato (ES)

15:45 – 16:00

Indications of HCT in Multiple Myeloma

Patrick Hayden (IE)

16:00 – 16:15

CAR-T for Multiple Myeloma

Luis Gerardo Rodríguez-Lobato (ES)

16:15 – 16:30

Strategies to Overcome Challenges in CAR-T Cell Therapy

Carlos Fernández De Larrea (ES)

16:30 – 16:40

*Case presentation:*

Daratumumab as a Novel Therapeutic Option for Refractory Pure Red Cell Aplasia

Following Major ABO-Incompatible Allogeneic HSCT

Nevena Besevic (RS)

16:40 – 17:00

Discussion and Q&A

17:00 – 17:45

## Keynote Lecture

**Chair:** Annalisa Ruggeri (IT)

Modulation of the microbiota in haematology: current status and perspectives

Mohamad Mohty (FR)



# 10<sup>th</sup> International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain

**Saturday, 6 September 2025**  
**Nurses' Track | Aula 4.1**

09:00 – 11:00	<b>Session I: Preparation, cell collection, conditioning and infusion</b> <b>Chairs:</b> Michelle Kenyon (UK) & Hilda Mekelenkamp (NL)	
09:00 – 09:10	Welcome & Introduction	Hilda Mekelenkamp (NL)
09:10 – 09:30	Right donor, right patient, right time	Annika Kisch (SE)
09:30 – 09:55	Preparing for transplant: all you need to know	Davide Bonomi (IT)
09:55 – 10:15	Conditioning regimens different approaches and why	Marijke Quaghebeur (BE)
10:15 – 10:40	Cell infusion: stem cell, CART and lymphocytes: exploring the differences	Sandrine Bremathas (UK)
10:40 – 11:00	CVCs - evidencing best practice	Solveig Adalsteinsdóttir (SE)
11:00 – 11:30	<b>Coffee Break</b>	
11:30 – 13:00	<b>Session II: Post infusion care</b> <b>Chairs:</b> Claudia Boglione (IT) & Marijke Quaghebeur (BE)	
11:30 – 11:50	Nutritional support – the current guidance	Katie Ahern (IE)
11:50 – 12:15	Infections and keeping our patients safe	Thomas Jézéquel (FR)
12:15 – 12:45	Early complications	Anna Serrahima (ES)
12:45 – 13:00	How to write an abstract	Hilda Mekelenkamp (NL)
13:00 – 14:00	<b>Lunch Break</b>	
14:00 – 15:15	<b>Session III: Transplant complications</b> <b>Chairs:</b> Thomas Jézéquel (FR) & Anna Serrahima (ES)	
14:00 – 14:15	Acute GvHD & graft management	Silvia Gnechi (IT)
14:15 – 14:30	cGvHD	John Murray (UK)
14:30 – 14:35	GvHD Q&A	
14:35 – 14:55	Conception, sex and sexuality	Iebe de Quick (BE)
14:55 – 15:15	Long term follow-up, QoL, and survivorship	Michelle Kenyon (UK)
15:15 – 15:45	<b>Coffee Break</b>	
15:45 – 16:30	<b>Session IV: Essential update</b> <b>Chairs:</b> Hilda Mekelenkamp (NL) & Annika Kisch (SE)	
15:45 – 16:05	Paediatric update	Hilda Mekelenkamp (NL)
16:05 – 16:25	Evolving treatments in auto-immune disease	Claudia Boglione (IT)
16:25 – 16:30	Closing remarks	Hilda Mekelenkamp (NL)
17:00 – 17:45	<b>Keynote Lecture (Paranimf)</b> <b>Chair:</b> Annalisa Ruggeri (IT) Modulation of the microbiota in haematology: current status and perspectives	<b>Mohamad Mohty (FR)</b>





# 10<sup>th</sup> International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain

Saturday, 6 September 2025  
Paediatrics' Track | Aula Magna

09:00 – 11:00

## Session I: Leukemias in children (PDWP)

**Chairs:** Krzysztof Kałwak (PL) & Benedetta E. Di Majo (IT)

09:00 – 09:25

Paediatric ALL TBI vs non-TBI

09:25 – 09:50

CAR-T cells in B-ALL

09:50 – 10:15

AML in 2025: Who and when to transplant?

10:15 – 10:40

CML: is there still a role for transplant in the era of TKIs?

10:40 – 10:50

**Case Presentation:**

Beyond remission: Uncertainties in Late-Onset Hepatic complications after CAR-T therapy and hematopoietic stem cell transplantation

Krzysztof Kałwak (PL)

Giovanna Lucchini (IT)

Dominik Turkiewicz (SE)

Herbert Pichler (AT)

José Antonio Flores (ES)

10:50 – 11:00

Discussion

11:00 – 11:30

## Coffee Break

11:30 – 13:00

## Session II: HSCT and Gene therapy in PIDS and metabolic disorders (IEWP)

**Chairs:** Maria Ester Bernardo (IT) & Anna-Lisa Lanz (DE)

11:30 – 11:45

Indications to allo-HSCT vs. HSC-GT in LSDs

Maria Ester Bernardo (IT)

11:45 – 12:10

Indications to allo-HSCT vs. HSC-GT in PIDs

Claire Booth (UK)

12:10 – 12:45

Which haploidentical platform to be employed in PID patients (TCR ab vs. pCY)?

Bénédicte Neven (FR)

12:45 – 13:00

Discussion

13:00 – 14:00

## Lunch Break

14:00 – 15:15

## Session III: From Fanconi Anemia + MDS. (SAAWP + MDS-EWOG)

**Chairs:** Luca Vinci (DE) & Su Han Lum (UK)

14:00 – 14:25

HSCT in Fanconi Anaemia

Su Han Lum (UK)

14:25 – 14:50

HSCT in MDS/JMML

Luca Vinci (DE)

14:50 – 15:00

**Case Presentation:**

A severe cutaneous graft-versus-host disease reaction in the setting of herpes simplex virus-1 infection and tissue repair deficiency

Paula Mazorra Roig (ES)

15:00 – 15:15

Discussion

15:15 – 15:45

## Coffee Break

15:45 – 16:55

## Session IV: HSCT vs Gene therapy in hemoglobinopathies (HWP)

**Chairs:** Josu de la Fuente (UK) & Esraa Khalil (OM)

15:45 – 16:10

HSCT and gene therapy in sickle cell disease

Josu de la Fuente (UK)

16:10 – 16:40

HSCT and gene therapy in thalassaemia

Mattia Algeri (IT)

16:40 – 16:50

**Case Presentation**

First experience of allogeneic hematopoietic stem cell transplantation for sickle cell disease patients in a low resource country (Tanzania)

Catherine Mhando (TZ)

16:50 – 17:00

**Case Presentation**

Cerebral infarcts associated with micro embolic phenomena in the setting of infective endocarditis after allogeneic hematopoietic stem cell transplantation for sickle cell disease

Lucas Anastacio (BR)

17:00 – 17:45

## Keynote Lecture (Paranimf)

**Chair:** Annalisa Ruggeri (IT)

Modulation of the microbiota in haematology: current status and perspectives

Mohamad Mohty (FR)



# 10<sup>th</sup> International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain

Sunday, 7 September 2025  
Main Track | *Paranimf*

09:00 – 10:00	<b>Session IX: Complications after HCT</b> <b>Chairs:</b> <i>Isabel Sanchez - Ortega (ES) &amp; Ibrahim Yakoub-Agha (FR)</i>	
09:00 – 09:15	Early Endothelial Complications	Ibrahim Yakoub-Agha (FR)
09:15 – 09:25	Neurological complications	Giorgio Orofino (IT)
09:25 – 09:40	Improving infectious complications	José Luis Piñana (ES)
09:40 – 09:50	<i>Case Presentation:</i> Refractory post-transplant associated thrombotic microangiopathy in an adult patient with severe aplastic anaemia: exploring diagnostic and therapeutic challenges	Andrea Lattanzi (IT)
09:50 – 10:00	<i>Case Presentation:</i> Haemophagocytic Lymphohistiocytosis and EBV reactivation in severe Systemic Sclerosis after Autologous Transplant	Maria Chiara Auriemma (IT)
10:00 – 11:15	<b>Session X: Optimizing Outcomes in Relapse Management</b> <b>Chairs:</b> <i>Yousif Hameed (UK) &amp; Jürgen Kuball (NL)</i>	
10:00 – 10:15	Immune Escape in Relapse	Cristina Toffalori (IT)
10:15 – 10:30	Role of DLI to improve outcomes	Jürgen Kuball (NL)
10:30 – 10:45	Graft manipulation for better outcomes	Moniek de Witte (NL)
10:45 – 10:55	<i>Case Presentation:</i> Management of Post-Transplant Relapse in a Young Adult Patient with Acute Myeloid Leukaemia: A Clinical Case	Alessandro Criscimanna (IT)
10:55 – 11:05	<i>Case Presentation:</i> Durable Remission with Glofitamab Post- HSCT in a Patient with Relapsed/Refractory Burkitt Lymphoma with CNS Involvement	Yashashree Gupta (UK)
11:05 – 11:15	<i>Case Presentation:</i> CC-486 as a Bridge to Allogeneic Transplantation in TP53-Mutated MDS del(5q): A Case Report and Reflection on GvHD Management in the Elderly	Anna Francesio (IT)
11:15 – 11:45	<b>Coffee Break</b>	
11:45 – 12:45	<b>Session XI: Next-Generation Strategies in HCT and CAR-T</b> <b>Chairs:</b> <i>Nicolaus Kröger (DE) &amp; Alberto Mussetti (ES)</i>	
11:45 – 12:00	Measurable residual disease	Nicolaus Kröger (DE)
12:00 – 12:15	Using Machine Learning and AI in HCT and CAR-T	Adrian Mosquera Orgueira (ES)
12:15 – 12:30	Immune-monitoring, why would we and should we?	Moniek de Witte (NL)
12:30 – 12:40	<i>Case Presentation:</i> Donor-derived CD45RA <sup>+</sup> T-Cell infusion for disseminated Adenovirus infection following haploidentical HSCT in a pediatric patient with CAEBV and Hodgkin Lymphoma	Francesca Ciritella (IT)
12:40 – 12:45	Discussion and Q&A	
12:45 – 13:00	<b>Poster awards and Closing Remarks</b> <b>Chairs:</b> <i>Anna Sureda (ES)</i>	



## Solveig Adalsteinsdóttir

Graduated with a BSc in Nursing (2007) and a Master's in Oncology (2017), she is Head of Nursing Development at the Cell Therapy Clinic, Karolinska University Hospital, Stockholm. She oversees strategic nursing care, research, and education, serves on the clinic and Cancer Theme nursing boards, and leads projects including home care for allogeneic patients and outpatient care for CAR-T patients.



## David Aguilar

Lymphoma survivor in remission after CAR-T therapy, actively engaged in sharing the patient perspective and experiences to foster awareness, education, and progress in hematology and cellular therapies.



## Katie Ahern

Katie Ahern, specialist dietitian in hematology and stem cell transplantation since 2018, works at St James' University Hospital BMT Unit. Former Lead Dietitian at King's College Hospital, she focuses on enteral feeding, GVHD, and late post-transplant effects.



## Tobias Alexander

Dr. Alexander is a consultant rheumatologist at Charité - University Medicine Berlin, heading the outpatient clinic. He focuses on connective tissue diseases and systemic vasculitides, researching autoreactive immunologic memory, biomarkers, targeted therapies, and regulatory T cells. He is EBMT ADWP secretary and IgG4-related disease coordinator for ERN ReCONNET.



**Mattia Algeri**

Dr. Mattia Algeri, pediatric hematologist at OPBG, specializes in optimizing allogeneic stem cell transplantation for malignant and non-malignant disorders, particularly hemoglobinopathies. He participates in gene therapy trials for  $\beta$ -thalassemia and sickle cell disease and develops strategies to prevent GVHD and enhance post-transplant immune recovery.



**Jose Aspa Cilleruelo**

Consultant Haematologist at Sheffield Teaching Hospitals, specializing in myeloid malignancies, bone marrow failure, and stem cell transplantation. Focused on autologous/allogeneic transplant care, survivorship research in multiple myeloma, EBMT registry studies, and medical education with an international training background.



**Anna Barata**

Dr. Barata is faculty at Massachusetts General Hospital and Harvard Medical School. Her research focuses on survivorship in hematologic cancer patients receiving adoptive cellular therapies, including CAR-T and stem cell transplant, examining patient-reported and neurocognitive outcomes, and developing supportive care interventions.



**Ali Bazarbachi**

Ali Bazarbachi, MD, PhD, is Professor of Medicine and Founding Director of the Bone Marrow Transplantation Program at the American University of Beirut. Trained in Paris, his research focuses on targeted therapies for hematologic malignancies. He holds leadership roles in EBMT, NCCN, and the International Academy for Clinical Hematology and has received multiple prestigious awards.





**Maria Ester Bernardo**

Dr. Bernardo is Head of the Pediatric Transplant Unit and Allogeneic Transplant Coordinator at San Raffaele, Milan. Group Leader at SR-TIGET and Associate Professor, she leads a gene therapy trial for Hurler Syndrome. Author of 100+ papers, she has an H-index of 49.



**Claudia Boglione**

BMT nurse since 2006, case manager for international patients, and EBMT ADWP nurse, with extensive experience in transplant care and patient management.



**Davide Bonomi**

Davide Bonomi, RN, MScN, has worked since 2019 at IRCCS Ospedale San Raffaele in Bone Marrow Transplant and Pediatric Immunohematology. Focused on nurse mentorship, he supports new graduates in complex clinical settings. Since 2023, he lectures on Clinical Nursing in Oncology and seeks to contribute to the Scientific Committee.



**Claire Booth**

Claire is Professor of Paediatric Immunology and Gene Therapy at UCL GOS ICH, leading pioneering stem cell gene therapy trials for immune, hematologic, and metabolic disorders. She manages patients with immunodeficiencies, focuses on HLH, and co-founded the AGORA Foundation for rare disease therapies.





## Sandrine Bremathas

Paediatric BMT coordinator at St Mary's Hospital, London, with 10 years' experience in pediatric hematology and non-malignant transplants. Specializes in red cell disorders and haemoglobinopathies, serving as EBMT Haemoglobinopathies Nurse Rep and UK Pediatric EBMT NAP representative.



## Enric Carreras

Dr. Enric Carreras, Senior Group Leader at Josep Carreras Leukaemia Research Institute, is a pioneering hematologist and former Director of the Stem Cell Transplantation Unit at Hospital Clínic. He specializes in SCT complications, autologous transplants for rare diseases, and endothelial damage, with 500+ publications and leadership in EBMT.



## Fabio Ciceri

Professor Fabio Ciceri, Director of Hematology, BMT Unit, and Blood Bank at San Raffaele Hospital, and full Professor at Vita-Salute San Raffaele University, leads the Comprehensive Cancer Center. His research advances haploidentical transplantation and pioneering cell and gene therapies for blood cancers and rare diseases.



## Alessandro Criscimanna

Dr. Criscimanna is a Hematology resident with a strong academic and clinical interest in the field of hematopoietic stem cell transplantation (HSCT). During residency training, he has been actively involved in the management of patients with acute leukemias, myelodysplastic syndromes, and lymphoproliferative disorders, with a particular focus on transplant eligibility, conditioning regimens, and post-transplant outcomes.



## Josu de la Fuente

Dr. Josu de la Fuente, Consultant Haematologist at Imperial College Healthcare NHS Trust and Professor of Practice at Imperial College London, directs the Pediatric BMT Programme, specializing in haemoglobinopathies, bone marrow failure, and gene therapy. He holds key roles in EBMT working parties and leads multiple gene therapy trials.



## Iebe De Quick

Iebe De Quick is Coordinator of Oncofertility and Surrogacy at Brussels IVF, Belgium's largest fertility center. She specializes in supporting cancer patients in fertility preservation and offers personalized care across various fertility subdomains.



## Moniek De Witte

Moniek de Witte, MD-PhD at UMC Utrecht, specializes in myeloid malignancies and non-malignant hematologic diseases. Her work spans clinical care and research, including stem cell transplantation with alpha-beta/CD19 depletion, personalized GVHD prophylaxis, and myeloablative conditioning. She leads a research team and actively contributes to Dutch SCT and EBMT initiatives.



## Benedetta Elena Di Majo

Pediatric resident at Fondazione IRCCS San Gerardo, Monza, focusing on hematology, immunology, and BMT. Trained at San Raffaele, Johns Hopkins, and Great Ormond Street. Active in research on rare immunodeficiencies and gene therapy, with strong interest in pediatric BMT and cellular therapies.



**Joanna Drozd-Sokolowska**

Haematologist at the Medical University of Warsaw and co-secretary of the EBMT Chronic Malignancies Working Party, actively contributing to research and clinical initiatives in hematologic malignancies.



**Carlos Fernandez de Larrea**

Carlos Fernández de Larrea, trained in hematology at Hospital Clínic, Barcelona, is Consultant, IDIBAPS research group leader, and Professor at the University of Barcelona. Experienced in CAR-T research for myeloma, he leads clinical and preclinical studies in multiple myeloma and monoclonal gammopathies.



**Jana Gawron**

Jana Gawron, PhD candidate in Hemato-Oncology at University Medical Center Freiburg, studies gastric graft-versus-host disease, exploring its mechanisms and therapies. Trained in molecular medicine in Freiburg and Washington University, she is also active in student representation and community engagement.



**Sebastian Giebel**

Prof. Sebastian Giebel is a hematology and transplantation specialist, heading the Bone Marrow Transplantation and Onco-Hematology Department at Maria Skłodowska-Curie Institute, Poland. He leads EBMT ALL subcommittee, presides over PALG, and has authored 300+ papers, awarded the Jędrzej Śniadecki Medal.





**Silvia Gnechi**

Since 2021, nurse in the Hematology and BMT Unit at San Raffaele Hospital, Milan, with a MSc in Nursing. Focused on HSCT patient care, nursing research, and education, she leads mentorship programs for new nurses, develops patient education tools, and promotes evidence-based nursing and Cancer Center accreditation standards.



**Raffaella Greco**

Senior Physician in the Hematology and BMT Unit at IRCCS San Raffaele Hospital, Milan, Italy. Specializes in hematopoietic stem cell transplantation and cellular therapies for malignant and non-malignant diseases. Active in EBMT, including ADWP Chair (2020-24) and EBMT Secretary (2024-present).



**Esra Gülderen**

Co-chair of the EBMT Trainee Committee.



**Carmelo Gurnari**

Carmelo Gurnari, MD, PhD, is Assistant Professor of Hematology at the University of Tor Vergata, Rome, and Research Associate at the Cleveland Clinic, USA. His work bridges clinical care and translational research in hematology and oncology.



**Yousif Hameed**

Dr. Yousif Hameed is a Haematology Specialist Registrar with an MBBS and BSc (Hons) from UCL. He focuses on stem cell transplantation and CAR-T therapy, with a strong commitment to advancing innovative treatments in malignant haematology and integrating them into patient care.



**Patrick Hayden**

Dr. Hayden is a consultant haematologist and clinical lead for the myeloma service at St James's Hospital, Dublin, and medical director of the Cryobiology Laboratory at the National Stem Cell Transplant Unit. Trained at UCD and Dana-Farber, he is Chair of the EBMT CMWP Plasma Cell Diseases subcommittee.



**Mette Hazenberg**

Dr. Mette Hazenberg is Professor of Hematology and Cell Therapy at Amsterdam UMC and Sanquin Research. Her research focuses on immunology of allogeneic HCT, including AML-specific therapeutic antibodies, graft-versus-host disease prevention via innate lymphoid cells and microbiome, and immune recovery impacting vaccine responses.



**Candice Hendricks**

Candice Hendricks is a pediatric hematologist and clinician scientist who completed her PhD at the University of Pretoria in 2024. She focuses on improving access to pediatric HSCT in South Africa, trained in Italy, and chairs South Africa's BloodSA Pediatric HSCT and Cell & Gene Therapy working parties.





# 10<sup>th</sup> International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain



**Thomas Jézéquel**

Advanced Nurse Practitioner in the Pediatric Hematology Unit at the University Hospital of Nantes, France. Member of the Scientific Committee of the EBMT Nurses Group.



**Piotr Kacprzyk**

Physician at the Haematology Department, Medical University of Warsaw, specializing in the diagnosis and treatment of hematologic disorders.



**Krzysztof Kalwak**

Prof. Kalwak, Chair of EBMT Pediatric Disease Working Party and Pediatric Hematology/Oncology & BMT at Wroclaw, Poland, pioneered pediatric CAR-T therapy in Poland and introduced autologous HSCT gene therapy for SCID-RAG1. National HSCT coordinator for PIDs, metabolic disorders, CML, and congenital neutropenia.



**Michelle Kenyon**

Michelle Kenyon, Consultant HCT Nurse, leads patient and caregiver support, long-term follow-up, and survivorship initiatives. Former EBMT Nurses' Group President, she advances nursing education, researches patient experience and transplant complications, and co-edits the EBMT Nurse Textbook.



**Esraa Khalil**

Pediatric specialist in hematology, oncology, and bone marrow transplantation (BMT), with expertise in managing malignant and non-malignant disorders and providing comprehensive care in transplantation and cellular therapies.



**Nicolaus Kröger**

Dr. Nicolaus Kröger is Professor of Medicine and Medical Director of Stem Cell Transplantation at University Medical Center Hamburg-Eppendorf, leading Germany's largest allogeneic transplant program. Board-certified in Hematology-Oncology and Internal Medicine, he is a former EBMT President and has authored over 950 publications in top journals.



**Jürgen Kuball**

Prof. Jürgen Kuball chairs Hematology at UMC Utrecht Cancer Centre and directs its stem cell transplantation program, focusing clinically on acute leukemia and allogeneic HCT. His research in tumor immunology and engineered immune cells led to co-founding GADETA and multiple patents. He chairs EBMT's LRAC since 2019.



**Anna-Lisa Lanz**

Dr. Anna-Lisa Lanz, MD, pediatrician and postdoctoral researcher trained at LMU and Oxford, specializes in inborn errors of adaptive immunity. She currently works as a fellow in pediatric oncology on the Bone Marrow Transplantation Unit at LMU Children's Hospital, focusing on primary immunodeficiencies.



**Giovanna Lucchini**

Pediatric transplant specialist with extensive expertise in HSCT for malignant and non-malignant disorders, peri-transplant immunotherapy, and administration of both autologous and allogeneic CAR-T cell therapies.



**Su Han Lum**

Dr. Su Han Lum, Honorary Consultant and Senior Clinical Research Fellow at Newcastle University, specializes in pediatric HSCT for inborn errors of immunity. She leads the Haplo+4kids trial, optimizing haploidentical transplants, and conducts multicenter studies to improve outcomes and long-term health in children with rare diseases, collaborating with EBMT since 2017.



**Annika M Kisch**

Nurse in hematology and stem cell transplantation since 1993, now RD&E leader at Lund University Hospital and Associate Professor at Lund University. Focused on patient, caregiver, and donor perspectives in allo-HCT and person-centred care. Former Chair of the EBMT Nurses Group Research Committee.



**Jamie Macleod**

Dr. Jamie Macleod, Visiting Research Associate at the University of Bristol, holds a PhD and MEng. His research focuses on smoothed particle hydrodynamics and implicit particle tracking, improving aircraft fuel sloshing simulations. He advances computational fluid dynamics for aerospace safety analysis.



**Mohamad Mohty**

Dr. Mohamad Mohty is Professor of Hematology and head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University, Paris. Former EBMT President and Acute Leukemia Working Party Chair, he founded the International Academy for Clinical Hematology. A fellow of the French National Academy of Medicine and chevalier de la Légion d'Honneur, he has published over 1,000 articles and serves as Editor-in-Chief of Bone Marrow Transplantation and Clinical Hematology International.





**Florent Malard**

Florent Malard, MD, PhD, is Professor of Hematology at Sorbonne Université and Saint-Antoine Hospital, Paris. Trained in Nantes, Paris, and MSKCC, his research focuses on allogeneic hematopoietic cell transplantation, immunology, microbiota, and multiple myeloma, with over 200 publications.



**Neema Mayor**

Dr. Neema Mayor is Director of Immunogenetics & Research Services at Anthony Nolan Research Institute and Honorary Lecturer at UCL Cancer Institute. Her research focuses on HLA and non-HLA genetic variants in unrelated donor HCT. She serves on multiple editorial boards and immunogenetics societies.



**Donal Mc Lornan**

Dr. Donal McLornan is a consultant in MPN, allogeneic transplant, and CAR-T at University College London Hospital, home to the UK's largest transplant and CAR-T program. He chairs EBMT's Chronic Malignancy Working Party, co-chairs its scientific council, and leads UK Blood Cancer MPN initiatives. His research focuses on myelofibrosis, MPN/MDS overlap, and allogeneic transplantation.



**Hilda Mekelenkamp**

Hilda Mekelenkamp is a pediatric stem cell transplant nurse and postdoctoral researcher at Leiden University Medical Centre, Netherlands. Her research focuses on stakeholder perspectives in stem cell therapy decision-making. She also serves as President of the EBMT Nurses Group.



## Adrián Mosquera Orgueira

Adrián Mosquera, PhD, is a hematologist and head of the Computational Hematology and Genomics Group at IDIS, Spain. His research applies AI, genomics, and precision medicine in oncohematology to predict therapy response and guide clinical decisions, integrating computational and molecular approaches in patient care.



## John Murray

Registered Nurse with extensive experience in haematology and BMT since 1991. Nurse Clinician at The Christie, leading on GvHD and late effects, and Trust Lead for Advanced Practice. Former EBMT NG President (2017-21), past Scientific Committee Chair, and Honorary Lecturer at Manchester University.



## Alberto Mussetti

Dr. Alberto Mussetti, trained in Hematology in Milan with a PhD in Cellular Therapy from Barcelona, coordinates the Cellular Therapy Program at Institut Català d'Oncologia. He leads GETH's lymphoma and myeloma group and EBMT's AI subcommittee, with training at MSKCC, Cornell, and CIBMTR.



## Bénédicte Neven

Prof. Bénédicte Neven is a pediatric immunologist and hematologist at Necker-Enfants Malades Hospital, Paris, and Professor at Université de Paris Cité. She leads the Pediatric Hemato-Immunology Unit and HSCT program, focusing on primary immunodeficiencies, gene and cell therapies, and pioneering clinical trials, with 100+ publications and leadership roles in EBMT and the European Reference Network for RITA.





## Michael Northend

Dr. Michael Northend is a consultant haematologist at UCL Hospitals, specializing in cellular immunotherapies and lymphoproliferative disorders. He leads clinical trials in lymphoma, including CAR T-cell therapies, and contributes to real-world evidence research as part of the UK Lymphoma Research Group.



## Giorgio Orofino

Dr. Giorgio Orofino is a Hematology-Oncology Fellow and Physician Scientist PhD candidate at Università Vita e Salute San Raffaele, Milan, specializing in hematologic malignancies, bone marrow transplantation, and cellular therapies for autoimmune disorders.



## VALENTÍN ORTIZ-MALDONADO

Valentín Ortiz-Maldonado, MD, PhD, trained in Hematology at Hospital Clínic (Barcelona), holds master's in transplantation and Immuno-Oncology, completed a PhD on CAR T ARI-0001, a postdoc at Fred Hutchinson, and is senior specialist in Oncoimmunotherapy at Hospital Clínic.



## Zinaida Peric

Zinaida Peric is a hematologist and Associate Professor at the University of Rijeka, Croatia, focusing on GVHD, gut microbiota, acute leukemias, and transplant complications. She leads the Hematology Department at University Hospital Centre Rijeka and chairs the EBMT GVHD Subcommittee.



## Herbert Pichler

Herbert Pichler, Associate Professor of Pediatrics at the Medical University of Vienna, is Consultant in Pediatric Oncology and Head of the Stem Cell Transplantation Program at St. Anna Children's Hospital since 2019, specializing in pediatric hematology, oncology and transplantation.



## Jose Luis Piñana

Specializes in infections in hematology patients and cell therapy recipients, focusing on prevention, management, and improving outcomes in these high-risk populations.



## Marijke Quaghebeur

Marijke Quaghebeur is a clinical nurse specialist in Hematology and HSCT at UZ Gent, focusing on patient education, psychosocial support, and nurse mentoring. Active in BHS and EBMT, she lectures at nursing colleges and has 20+ years advancing cellular therapy nursing in Belgium.



## Alexandros Rampotas

Alex Rampotas, MD, PhD, is an Academic Clinical Lecturer at UCL Cancer Institute, UK, specializing in hematology. Trained in Greece and the UK, his research focuses on cellular therapies and myeloproliferative neoplasms, including developing a novel CAR-T therapy for calreticulin-mutated myelofibrosis.



**Luis Gerardo Rodríguez-Lobato**

Dr. Luis Gerardo Rodríguez-Lobato, hematologist and physician-scientist at Hospital Clínic and Univ. of Barcelona, focuses on monoclonal gammopathies and CAR-T therapy for myeloma. CRIS Translational Talent fellow, he advances CAR-T innovation as IDIBAPS investigator and clinical expert.



**Annalisa Ruggeri**

Annalisa Ruggeri, senior physician at San Raffaele BMT Unit, Milan, leads clinical research as Eurocord Scientific Chair and EBMT CTIWP Chair. EBMT educational council rep and EHA EBAH member, she has 200+ publications (H-index 53) and is a frequent speaker at major hematology conferences.



**Isabel Sánchez-Ortega**

Hematologist specialized in hematopoietic cell transplantation at Institut Català d'Oncologia, focusing on long-term complications, chronic GvHD, infections, and aplastic anaemia. Active in EBMT for 20 years, leading trials, supporting JACIE accreditation, and serving as Medical Officer and Education Directorate Director.



**Anna Serrahima Mackay**

Hemato-oncology nurse since 2012, specializing in transplant care, unit management, and JACIE accreditation. Active member of the EBMT Nurses Group, contributing to the Scientific Committee since 2024.





**John Snowden**

Professor John Snowden is Professor of Haematology at the University of Sheffield and Director of Blood and Marrow Transplantation. Trained in the UK, New Zealand, and Australia, he has 20+ years of EBMT involvement, served as Secretary, led BSBMTCT, authored ~400 publications, and contributed to key clinical guidelines.



**Anna Sureda**

Anna Sureda, MD, PhD, is Head of Clinical Hematology at Institut Català d'Oncologia. She specializes in lymphoma and multiple myeloma, focusing on immunotherapy and stem-cell transplantation. She has held leadership roles in EBMT, CIBMTR, and is President of the EBMT since March 2022.



**Cristina Toffalori**

Dr. Cristina Toffalori, researcher at San Raffaele Scientific Institute (Milan), investigates leukemia immune escape after HSCT. She has identified key genomic and microenvironmental mechanisms guiding relapse and therapy, earning the EBMT Jon J. van Rood (2020) and EFI Julia Bodmer (2021) Awards.



**Dominik Turkiewicz**

Dr. Dominik Turkiewicz, MD, PhD, is a pediatric hematologist-oncologist and Senior Consultant at University Hospital in Skåne, Sweden. Clinical Director of the Pediatric Stem Cell Transplant program in Lund since 2018, his research focuses on AML, MDS/SAA, hemoglobinopathies, haploidentical HSCT, cellular therapies, and trial design.



**Sara Vallejo Diez**

BSc in Biology (University of Salamanca) and PhD in Biomedical Research (University of Valladolid), with postdoc experience in iPSCs and organoids at CSIC. Since 2021, Production Manager at the JACIE-certified Advanced Therapies Unit, Cantabrian Blood and Tissue Bank, specializing in GMP-compliant ATMP manufacturing.



**Luca Vinci**

Pediatrician specializing in stem cell transplantation and pediatric hematologic malignancies, trained in Pavia and Freiburg. Works in the BMT unit and serves as study physician for EWOG-MDS/SAA. Vice Co-Chair of the EBMT Trainee Committee, promoting pediatric perspectives and collaboration in transplant care.



**Ibrahim Yakoub-Agha**

Prof. Ibrahim Yakoub-Agha, President-Elect of EBMT, specializes in allogeneic hematopoietic cell transplantation and gene/cellular therapy. Former CMWP Chair and SFGM-TC President, he leads EBMT guidelines, edits Current Research in Translational Medicine, and has authored 650+ publications.





# 10<sup>th</sup> International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain

## WITH THANKS TO OUR SPONSORS

Industry Symposium Partner



Gold Partners



Silver Partner

